Endothelial inflammation via TNF-α, IL-1β, or IL-6 pro-inflammatory cytokines favors leukocyte recruitment, endothelial dysfunction and activation of blood coagulation making interleukin-driven proatherothrombotic processes a potential pharmacological target explored in several clinical trials51,52. This evidence concerns the gene IL1B and inflammatory response.